Genmab A/S (NASDAQ:GMAB) Expected to Post FY2024 Earnings of $0.88 Per Share

Genmab A/S (NASDAQ:GMAB) – Analysts at William Blair lowered their FY2024 earnings per share estimates for Genmab A/S in a note issued to investors on Wednesday, April 17th. William Blair analyst M. Phipps now forecasts that the company will post earnings per share of $0.88 for the year, down from their previous forecast of $0.89. The consensus estimate for Genmab A/S’s current full-year earnings is $1.06 per share. William Blair also issued estimates for Genmab A/S’s FY2025 earnings at $1.05 EPS.

Other research analysts have also recently issued research reports about the company. Morgan Stanley reiterated an “underweight” rating on shares of Genmab A/S in a research report on Tuesday, March 26th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research report on Thursday, April 4th. BMO Capital Markets upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $46.00 to $48.00 in a research report on Friday, February 23rd. Truist Financial reiterated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research report on Tuesday, March 26th. Finally, Citigroup cut Genmab A/S from a “neutral” rating to a “sell” rating in a research report on Monday, January 22nd. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Genmab A/S presently has an average rating of “Hold” and a consensus price target of $48.50.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $28.70 on Friday. The stock has a fifty day moving average price of $29.38 and a two-hundred day moving average price of $30.30. The stock has a market capitalization of $18.98 billion, a price-to-earnings ratio of 29.90, a PEG ratio of 2.05 and a beta of 0.99. Genmab A/S has a 1 year low of $26.32 and a 1 year high of $42.72.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.02. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. The firm had revenue of $675.29 million during the quarter, compared to the consensus estimate of $678.14 million.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. increased its position in Genmab A/S by 1.7% during the 1st quarter. Rockefeller Capital Management L.P. now owns 18,508 shares of the company’s stock worth $698,000 after purchasing an additional 310 shares in the last quarter. Ameriprise Financial Inc. increased its position in Genmab A/S by 5.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 6,268 shares of the company’s stock worth $221,000 after purchasing an additional 337 shares in the last quarter. Geode Capital Management LLC increased its position in Genmab A/S by 1.0% during the 2nd quarter. Geode Capital Management LLC now owns 41,715 shares of the company’s stock worth $1,586,000 after purchasing an additional 408 shares in the last quarter. HBK Sorce Advisory LLC increased its position in Genmab A/S by 4.8% during the 3rd quarter. HBK Sorce Advisory LLC now owns 9,139 shares of the company’s stock worth $322,000 after purchasing an additional 419 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in Genmab A/S by 86.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock worth $38,000 after purchasing an additional 498 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.